ERIS Lifescience

Why is ERIS Lifesciences Ltd falling/rising?

As of 11-Jun, ERIS Lifesciences Ltd's stock price is 1,366.75, with a slight increase today but a year-to-date decline of 9.11% and a 20.31% drop over the past year. Despite today's minor rise, the stock shows mixed investor sentiment and reduced trading volume, indicating broader negative trends.

As of 11-Jun, ERIS Lifesciences Ltd's stock price is currently at 1,366.75, reflecting a slight increase of 1.0 (0.07%). Despite this minor rise today, the stock has shown a negative performance over various periods, including a decline of 9.11% year-to-date and a significant drop of 20.31% over the past year. <BR><BR>Today's trading session saw the stock reach an intraday high of Rs 1399.5, which is a 2.47% increase, but it also experienced a low of Rs 1338.4, marking a decrease of 2%. This volatility indicates mixed investor sentiment. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 68.18% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>On a positive note, the company maintains a high management efficiency with a return on capital employed (ROCE) of 15.33% and a strong ability to service its debt, evidenced by a healthy EBIT to interest ratio of 26.10. Furthermore, the company reported positive financial results, including a low debt-equity ratio of 0.60 times and a significant growth in profit before tax.<BR><BR>Overall, while the stock is experiencing a slight rise today, the broader context shows a trend of falling prices over the longer term, influenced by reduced trading volume and mixed performance metrics.

Which are the latest news on ERIS Lifescience?

What does ERIS Lifescience do?

ERIS Lifesciences Ltd manufactures and markets pharmaceutical products, operating in the Small Cap market with a market cap of INR 18,926 Cr. As of March 2026, it reported net sales of 757 Cr and a net profit of 282 Cr.

Overview:<BR>ERIS Lifesciences Ltd is engaged in the manufacturing and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and operates in the Small Cap market-cap bracket.<BR><BR>History:<BR>ERIS Lifesciences Ltd was incorporated on January 25, 2007, and changed its name to 'Eris Lifesciences Private Limited' on February 9, 2007. The company was converted into a Public Limited Company and renamed 'Eris Lifesciences Limited' on February 2, 2017. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 757 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 282 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 18,926 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.53%<BR>- Debt Equity: 0.59<BR>- Return on Equity: 16.20%<BR>- Price to Book: 4.85<BR><BR>Contact Details:<BR>Address: 8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-30451000 <BR>Email: complianceofficer@erislifesciences. <BR>Website: http://www.eris.co.in

How big is ERIS Lifescience?

As of 10th June, ERIS Lifesciences Ltd has a market capitalization of 18,926.00 Cr, with recent net sales of 3,129.42 Cr and net profit of 619.51 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: ERIS Lifesciences Ltd has a market capitalization of 18,926.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,129.42 Cr, while the sum of Net Profit for the same period is 619.51 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 2,854.36 Cr, and Total Assets amount to 6,744.13 Cr.

Who are in the management team of ERIS Lifescience?

The management team of ERIS Lifescience includes Amit Indubhushan Bakshi (Chairman and Managing Director), Kaushal Kamlesh Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan (all Whole-Time Directors), and several Independent Non-Executive Directors: Sujesh Vasudevan, Prashant Gupta, Rajeev Narotam Dalal, and Kalpana Unadkat. This team combines diverse expertise and leadership for the company.

The management team of ERIS Lifescience includes the following key individuals:<BR><BR>1. **Amit Indubhushan Bakshi** - Chairman and Managing Director (CMD) & Executive Director<BR>2. **Kaushal Kamlesh Shah** - Whole-Time Director (WTD) & Executive Director<BR>3. **Inderjeet Singh Negi** - Whole-Time Director (WTD) & Executive Director<BR>4. **Krishnakumar Vaidyanathan** - Executive Director, Whole-Time Director (WTD), and Chairman<BR>5. **Sujesh Vasudevan** - Independent Non-Executive Director<BR>6. **Prashant Gupta** - Independent Non-Executive Director<BR>7. **Rajeev Narotam Dalal** - Independent Non-Executive Director<BR>8. **Kalpana Unadkat** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Should I buy, sell or hold ERIS Lifesciences Ltd?

Who are the peers of the ERIS Lifescience?

ERIS Lifescience's peers include Neuland Labs, Astrazeneca Pharma, Pfizer, Granules India, and others. Management risk varies from excellent to below average among peers, with Granules India showing the highest 1-year return at 45.45%, while ERIS Lifescience has a return of -18.83%.

Peers: The peers of ERIS Lifescience are Neuland Labs., Astrazeneca Phar, Pfizer, Granules India, OneSource Speci., Caplin Point Lab, Cohance Life, Natco Pharma, and Jubilant Pharmo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar and Granules India, while Good management risk is found at Neuland Labs., Pfizer, ERIS Lifescience, Caplin Point Lab, and Natco Pharma, and the rest. Below Average management risk is present at OneSource Speci. and Jubilant Pharmo, while Average management risk is noted at Cohance Life. Growth is Excellent at Granules India, while Below Average growth is seen at Astrazeneca Phar, Pfizer, ERIS Lifescience, Neuland Labs., Caplin Point Lab, Natco Pharma, OneSource Speci., and Jubilant Pharmo, and the rest. Cohance Life has Average growth. Capital Structure is Excellent at Astrazeneca Phar, Pfizer, Granules India, Caplin Point Lab, and Natco Pharma, while Good capital structure is found at ERIS Lifescience, and the rest have Below Average or Average capital structures.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 45.45%, while Cohance Life has the lowest at -57.75%. ERIS Lifescience's 1-year return of -18.83% is significantly lower than Granules India’s but higher than Cohance Life’s. Additionally, OneSource Speci., Cohance Life, Natco Pharma, and Jubilant Pharmo have negative six-month returns.

Has ERIS Lifesciences Ltd declared dividend?

Yes, ERIS Lifesciences Ltd has declared a dividend of 721%, amounting to ₹7.35 per share, with an ex-date of February 13, 2025. While recent total returns have varied, the company has shown strong growth over the longer term, particularly in the 2 to 5-year periods.

ERIS Lifesciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 721%<BR>- Amount per share: 7.35<BR>- Ex-date: Feb-13-2025<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 0.17%, the dividend return was 0.53%, resulting in a total return of 0.7%.<BR><BR>Over the 6-month period, the price return decreased by 19.21%, while the dividend return contributed 0.44%, leading to a total return of -18.77%.<BR><BR>For the 1-year period, the price return was down by 11.53%, with a dividend return of 0.46%, culminating in a total return of -11.07%.<BR><BR>In the 2-year period, the price return increased by 48.03%, and the dividend return was 1.59%, resulting in a total return of 49.62%.<BR><BR>During the 3-year period, the price return rose by 119.67%, with a dividend return of 2.24%, leading to a total return of 121.91%.<BR><BR>For the 4-year period, the price return was up by 87.01%, while the dividend return contributed 3.36%, resulting in a total return of 90.37%.<BR><BR>In the 5-year period, the price return increased by 89.77%, with a dividend return of 3.96%, leading to a total return of 93.73%.<BR><BR>Overall, ERIS Lifesciences Ltd has declared a significant dividend, and while recent total returns show variability, the longer-term performance indicates strong growth, particularly over the 2 to 5-year periods.

Are ERIS Lifesciences Ltd latest results good or bad?

ERIS Lifesciences Ltd's latest results show a significant net profit increase of 200.10% year-on-year, largely due to a one-time tax reversal, but revenue growth has slowed to 7.27% and declined sequentially by 6.30%, indicating mixed performance and raising concerns about sustainability. Investors should consider these factors when assessing the company's future prospects.

ERIS Lifesciences Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹281.61 crores for Q4 FY26, which is a remarkable 200.10% increase year-on-year. This impressive growth in net profit is primarily attributed to a one-time tax reversal that inflated the earnings, suggesting that the underlying operational performance may not be as robust as the headline figure indicates.<BR><BR>On the other hand, the revenue growth has shown signs of deceleration, with a year-on-year increase of only 7.27%, down from 28.02% in the same quarter last year. Additionally, there was a sequential decline of 6.30% in revenue compared to the previous quarter, which raises concerns about the sustainability of growth.<BR><BR>While the operating margin remains strong at 36.36%, reflecting effective cost management, the overall financial performance is clouded by the artificial boost from the tax reversal. Furthermore, the company has been underperforming compared to its sector peers, which adds to the cautious outlook.<BR><BR>In summary, while the net profit figure is impressive, the deceleration in revenue growth and reliance on one-time items for profit enhancement suggest that the results are not entirely positive. Investors may need to consider these factors carefully when evaluating the company's future prospects.

When is the next results date for ERIS Lifesciences Ltd?

The next results date for ERIS Lifesciences Ltd is 13 February 2026.

The next results date for ERIS Lifesciences Ltd is scheduled for 13 February 2026.

Is ERIS Lifescience technically bullish or bearish?

As of December 1, 2025, ERIS Lifescience's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bearish MACD and KST indicators, while moving averages suggest a slight bullish stance on the daily chart.

As of 1 December 2025, the technical trend for ERIS Lifescience has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bearish on both weekly and monthly time frames, while the Bollinger Bands show a bearish signal weekly but mildly bullish monthly. The moving averages indicate a mildly bullish stance on the daily chart, contrasting with the bearish signals from the KST on both weekly and monthly time frames. The Dow Theory suggests a mildly bullish trend on the weekly chart, but there is no clear trend on the monthly. Overall, the lack of strong bullish or bearish signals and the sideways trend indicate a neutral stance with no clear strength in either direction.

How has been the historical performance of ERIS Lifescience?

ERIS Lifescience has shown significant growth, with net sales increasing from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025, and operating profit rising from 376.60 Cr to 1,035.56 Cr. However, profit after tax fluctuated, peaking at 406.11 Cr in March 2022 and declining to 351.84 Cr by March 2025.

Answer:<BR>The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020.<BR><BR>Breakdown:<BR>ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.

Is ERIS Lifescience overvalued or undervalued?

As of September 5, 2025, ERIS Lifescience is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 60.82 and EV to EBITDA ratio of 24.71, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 26.09% that underperformed against the Sensex's 3.29%.

As of 5 September 2025, the valuation grade for ERIS Lifescience has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 60.82, an EV to EBITDA ratio of 24.71, and a PEG ratio of 37.14, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla is more attractively valued with a PE of 23.25 and an EV to EBITDA of 16.37. The high valuation metrics of ERIS Lifescience suggest that it is trading at a premium compared to its peers, which reinforces the conclusion of being overvalued. Notably, despite recent stock performance showing a 26.09% return year-to-date, it has underperformed against the Sensex's 3.29% return during the same period.

Who are the top shareholders of the ERIS Lifescience?

The top shareholders of ERIS Lifescience include promoter Amit Indubhusan Bakshi with 42.84%, mutual funds holding 16.59%, foreign institutional investors at 8.43%, and the highest public shareholder, Lilac Investments Limited, with 8.79%. Individual investors collectively own 9.16% of the shares.

The top shareholders of ERIS Lifescience include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Amit Indubhusan Bakshi, owning 42.84% of the company. Additionally, mutual funds hold 16.59% of the shares, represented by 22 schemes, while foreign institutional investors (FIIs) account for 8.43% through 135 different entities. The highest public shareholder is Lilac Investments Limited, which holds 8.79%. Individual investors collectively own 9.16% of the shares.